Table 4.
Monthly direct and indirect per patient costs of adjuvant treatment for stage III CRC
| Capecitabine-based group | 5-FU/LV-based group | Unadjusted difference* | P value | Adjusted difference* | P value | |
|---|---|---|---|---|---|---|
| Mean (SD) | Mean (SD) | |||||
| Direct cost | ||||||
| Medical cost | ||||||
| Ambulatory cost | 6410.32 (4116.36) | 4636.80 (5041.69) | −1773.52 | 0.0548 | −603.50 | 0.2981 |
| Outpatient chemotherapy cost | 2856.64 (6854.69) | 10626.70 (17649.99) | 7770.06 | 0.0249 | 1994.60 | 0.2555 |
| Inpatient chemotherapy cost | 462.59 (3200.74) | 26386.21 (24329.36) | 25923.62 | <0.0001 | 14718.53 | 0.0009 |
| Side effects of treatment cost | 151.49 (1027.40) | 11857.91 (10068.21) | 11706.42 | <0.0001 | 7324.83 | <0.0001 |
| Non-medical cost | ||||||
| Travel cost | 51.56 (64.34) | 56.67 (138.52) | 5.11 | 0.8464 | 2.52 | 0.8906 |
| Nursing aide | 397.85 (2863.34) | 1366.67 (4802.90) | 968.82 | 0.3023 | 723.86 | 0.0121 |
| Alternative care | 56.99 (333.10) | - | −56.99 | 0.1024 | −46.21 | 0.0086 |
| Total direct cost per patient | 10387.44 (9016.48) | 54930.95 (27747.10) | 44543.51 | 0.3374 | 25172.06 | <0.0001 |
| Indirect cost | ||||||
| Loss of productivity | 862.01 (1250.5) | 1654.77 (1168.69) | 792.76 | 0.003 | 140.27 | 0.411 |
| Loss of productivity for accompanying relatives | 6502.90 (9445.88) | 12474.00 (8802.9) | 5971.10 | 0.003 | 1059.14 | 0.411 |
| Total indirect cost per patient | 7364.91 (10696.38) | 14128.77 (9971.59) | 6763.86 | 0.003 | 1199.41 | 0.411 |
| Total cost per patient | 17752.35 (12907.36) | 69059.72 (26313.49) | 51307.37 | <0.0001 | 26371.47 | <0.0001 |
* Values greater than zero reflect a higher monthly expenditure during 5-FU/LV regimens